Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses.

Publication date: Mar 27, 2024

To evaluate the antibody response following the initial four doses of mRNA vaccines (BNT162b2 or mRNA-1273) in SARS-CoV-2-nacEFve healthy adults and investigate factors influencing antibody titer increases, this prospective cohort study was conducted in Japan from March 2021. The study included participants who received either the 1st and 2nd doses (n = 467), 3rd dose (n = 157), or 4th dose (n = 89). Blood samples were collected before and up to 6 months after each dose, and anti-receptor-binding domain antibody levels were measured. Multivariate analysis (usin multiple linear regression or linear mixed models) revealed several factors significantly associated with higher post-vaccination antibody levels, including mRNA-1273 vaccine (after the 1st and 2nd dose), male gender (after the 3rd and 4th doses), younger age (after the 1st and 2nd dose), non-smoking status (after the 2nd dose), non-use of immunosuppressive agents (after the 1st dose), higher pre-vaccination antibody titers (after the 2nd, 3rd, and 4th doses), and higher post-vaccination fever (after the 2nd and 4th doses). Furthermore, longer intervals since the last dose were significantly associated with higher antibody levels after the 3rd and 4th doses. These findings provide valuable insights for optimizing vaccination strategies.

Open Access PDF

Concepts Keywords
Bnt162b2 1st
Japan 2nd
Models 3rd
Vaccines 4th


Type Source Name
disease VO vaccination
disease VO COVID-19 vaccine
disease VO antibody titer
disease VO dose
disease IDO blood
disease VO vaccine
drug DRUGBANK Coenzyme M
disease MESH COVID 19
disease MESH Infectious Diseases
disease MESH Infection
disease VO primary vaccination
disease MESH obesity
drug DRUGBANK Ethanol
disease MESH hypertension
disease IDO history
disease MESH dyslipidemia
disease MESH contraindications
drug DRUGBANK Methionine
drug DRUGBANK Methylergometrine
disease VO vaccine dose
disease VO injection
disease VO USA
disease IDO assay
disease MESH underweight
disease VO vaccinated
drug DRUGBANK Pentaerythritol tetranitrate
pathway REACTOME Immune System
disease IDO production
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Nicotine
disease VO titer
disease VO frequency
disease IDO immune response
disease VO age
disease MESH Hyperlipidemia
disease VO effectiveness
disease VO population
disease IDO cell
disease VO efficient
disease VO vaccine efficacy
disease VO Gap
disease MESH influenza
disease VO pregnant women
disease VO Optaflu
disease VO protocol
disease IDO process

Original Article

(Visited 1 times, 1 visits today)